CA-PERSONALIS,-INC.
18.11.2020 14:02:04 CET | Business Wire | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia.
The company will showcase both their platforms, ImmunoID NeXT™ and NeXT Liquid Biopsy™.
ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample, thus maximizing the biological information that can be generated from a precious tumor specimen.
NeXT Liquid Biopsy , a first-of-its-kind, high-performance exome-wide liquid biopsy assay, provides a unique ability to evaluate the cancer ecosystem and advance the development of next-generation therapies. While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies has demonstrated there can be more to a cancer’s genotypic profile than that found in a single tissue biopsy. Therefore, the combination of NeXT Liquid Biopsy and ImmunoID NeXT delivers the most comprehensive view of a cancer’s mutational landscape by evaluating both the tissue and blood. NeXT Liquid Biopsy enables investigation into key applications such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. In this presentation, we’ll highlight data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of reference standards and patient samples.
Following are details for the Personalis presentations.
Scientific Poster Presentation
Poster Number |
Title & Presenter |
Dates |
||
40
|
Sensitive detection and monitoring of genetic alterations in circulating cfDNA with an enhanced whole-exome approach
|
NOV 18-19 | Online |
Following are details of an industry-sponsored symposium which will be presented at the meeting.
Satellite Symposia
Title |
Title & Presenter |
Dates |
||
Sponsored Symposia |
NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics
|
NOV 18-19 | On Demand |
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform ® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc ).
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the ImmunoID NeXT Platform, Personalis’ services for the VA MVP, the company’s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005479/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LPs Expect Private Markets Managers to Level Up in 2027: SS&C Intralinks Survey5.11.2026 15:00:00 CET | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the publication of the 2027 LP Survey. In association with Reuters Insights, SS&C Intralinks surveyed 400 professionals working in private markets, including 370 limited partners and allocators, to understand how the alternative investments market will change in the next 12 months.* “Alternatives once again delivered in 2026, and LPs are still committing capital, but their expectations of managers continue to rise,” said Ken Bisconti, general manager of SS&C Intralinks. “Technology and data capabilities now rank among the most important criteria for selecting managers, alongside investment strategy. Performance alone is no longer enough. For nearly one-third of allocators, a credible artificial intelligence (AI) strategy is now a prerequisite for allocating capital to a manager.” Key findings from the report include: Alternatives portfolios continue to outperform. 62% of respondents said their portfolios exceeded expectati
European Commission expands license for Alfasigma’s Jyseleca® (filgotinib) with approval of new indication, treatment of adults with axial spondylarthritis5.11.2026 15:00:00 CET | Press release
Jyseleca® (filgotinib) has received expanded approval for the treatment of patients with active axial spondylarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have not responded adequately to conventional therapy. EC approval follows a positive opinion from the CHMP in September 2026 and offers a new treatment option for people living with inadequately controlled axSpA in Europe. An application has been submitted to the MHRA for UK approval and is under review. In the OLINGUITO Phase 3 study, improvements in the signs and symptoms of axSpA – including spinal pain – were observed early and maintained over 52 weeks of treatment with filgotinib. This new indication builds on previous approvals for Jyseleca® for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis in Europe and the United Kingdom. The information contained within this press release is for the purpose of scientific exchange. It is intended for scientific, financia
Shonan Beauty Clinic Named to Newsweek’s “World’s Best Hospitals & Clinics for Medical Tourism 2027”5.11.2026 15:00:00 CET | Press release
Recognized in two Plastic & Reconstructive Surgery categories, liposuction and breast augmentation, among leading medical institutions across 13 countries SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced that Shonan Beauty Clinic, one of the clinic brands it supports, has been named to “World’s Best Hospitals & Clinics for Medical Tourism 2027,” an international ranking presented by Newsweek in partnership with Statista. The clinic was recognized in the Plastic & Reconstructive Surgery field, in both the liposuction and breast augmentation categories. The ranking covers six specialty fields across 13 countries. Within Plastic & Reconstructive Surgery, which comprises breast augmentation, liposuction, and rhinoplasty, each of the three categories names the top 75 institutions, and Shonan Beauty Clinic was recognized in two. T
Mohammed Bin Rashid Library to host third Dubai International Library and Publishing Summit under the theme “Architecture of Trust: AI and the Future of Knowledge Institutions”5.11.2026 14:43:00 CET | Press release
Mohammed Bin Rashid Library has announced the third edition of the Dubai International Library and Publishing Summit, taking place on 16 and 17 November 2026 under the theme “The Architecture of Trust: AI and the Future of Knowledge Institutions”. The Summit will bring together experts from libraries, museums, publishing houses, universities, research centres, cultural institutions and the technology sector worldwide to explore the future of knowledge institutions in the age of artificial intelligence. This year’s edition will feature more than 50 speakers representing over 40 organisations, across more than 20 panel discussions, keynote addresses and specialist workshops. The Summit will bring together local and international institutions, including leading UAE-based entities such as Zayed National Museum, the Technology Innovation Institute (TII) and Natural History Museum in Abu Dhabi, alongside international institutions such as the Leverhulme Centre for the Future of Intelligence
Current Chemicals Expands U.S. Production of Rare-Earth Fluorides With New Investment From Momentum Global Ventures5.11.2026 14:14:00 CET | Press release
Current Chemicals receives additional capital to scale U.S. capacity for critical rare-earth fluorides used in magnets, advanced coatings, and alloys Current Chemicals, Inc. (“CCI”), one of the few U.S. companies converting separated rare-earth oxides into the fluorides used to make rare-earth metals and magnets, today announced an additional investment from its lead shareholder, Momentum Global Ventures (“MGV”). The investment will significantly increase CCI’s production of neodymium fluoride, dysprosium fluoride, and other key rare-earth fluorides in Cleveland. The funding adds infrastructure, equipment and engineering staff for fluorides of neodymium, dysprosium, terbium, gadolinium, yttrium, scandium, lanthanum, and lithium for reducing light rare-earths to metal: key inputs for permanent magnets, advanced coatings, and alloys. Neodymium fluoride and dysprosium fluoride are key feedstocks for the metal at the core of high-performance magnets in electric motors, wind turbines and de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom